Psychedelic highlights | February 08 – 12

Shares :

Psychedelic highlights | February 08 – 12

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

M2Bio SciencesWUHN$0.939+ 114.8 %
Field TripFTRP$8.00+ 43 %
Psyched WellnessPSYC$0.60+ 39.5 %
NuminusNUMI$1.82+ 25.8 %
Revive TherapeuticsRVV$0.69+ 25.4 %
MindMedMMED$5.06+ 15.3 %
Red Light HollandsTRIP$0.60+ 15.3 %
Mind CureMCUR$0.63+ 8.6 %
CompassCMPS$48.75+ 5.4 %
Cybin Inc. CYBN$2.010+ 0.4 %

Story of the week

1. Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program [news release]

Revive Therapeutics is pleased to provide a corporate update on its cannabinoid pharmaceuticals program specifically as it relates to the clinical development of Cannabidiol (“CBD”) in the treatment of rare diseases and the Company’s novel drug delivery technology.

Read the full news HERE

2. MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds [news release]

MindMed Inc. announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.

As part of this partnership, MindMed and MindShift Compounds AG have agreed to develop next-gen psychedelic and empathogenic substances together.

Read the full news HERE

3. Medspresso Partners up with Zootly: South Africa’s Leading Cannabis Destination [news release]

M2Bio Sciences is pleased to share the following update regarding its MedspressoTm brand focused on creating premium African functional beverages:

This past week MedspressoTm set the seal on its alliance with South African retailer: Zootly.

Read the full article HERE

4. Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing [news release]

Numinus has closed its acquisition of Mindspace Psychology Services Inc. (DBA Mindspace Wellbeing), a leader and pioneer in psychedelic programming. The purchase agreement was previously announced on December 15, 2020

Read the full news HERE

5. Nova Mentis Psilocybin Approved for Shipment to Italy and Appoints Gary R. Harlem to Scientific Advisory Board [news release]

Nova Mentis Life Science Corp. was notified by its U.S. drug manufacturer that the required controlled substances export application had been approved by the U. S. Department of Justice Drug Enforcement Division (DEA). 

And more, Nova Mentis announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately. 

Read the full news HERE

6. Core One Labs Prepares First in Series of Patent Applications and Highlights Key Points from International Investor Call [news release]

Core One Labs  is pleased to announce preparations for filing a patent application encompassing its proprietary biosynthetic psilocybin production system.

And more, Core One Labs provided participants an update on the Company’s current Intellectual Property and patent application process, cost to produce psilocybin, and the commercial viability.

Read the full news HERE

7. Lobe Sciences Retains Jolt Communications to Increase Investor Awareness [news release]

Lobe Sciences is pleased to announce that it has retained Jolt Communications LLC (“Jolt“) to lead its investor relations efforts.

Philip Young, CEO of Lobe, states, “We are pleased to work with Jolt in an effort to bolster our communications with the investment community

Read the full news HERE

8. Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica [news release]

Field Trip  is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi in Mona, Jamaica. The research facility, which is opening as part of Field Trip’s previously announced strategic partnership with the University of West Indies

Read the full news HERE

9. Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller and Appoints Dr. Joel Castellanos as Clinical Advisor [news release]

Tryp Therapeutics  announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders.

And more, Tryp Therapeutics announced it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join the company’s Scientific Advisory Board. 

Read the full news HERE

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :